View More Recent Stories
-
Summit Therapeutics (SMMT) Reports Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC
-
Increasing unusual put option volume: CARR SMMT TT PLCE VSAT ZI HTGC VLY FL APH
-
Increasing unusual call option volume: SLQT IBKR SMMT ZION XME MU FRWD ORCL RH NGD
-
Increasing unusual option volume: FULC WGO EWY SMMT CRC WOOF DBRG PNR FHN
-
Summit Therapeutics (SMMT) Announces 10.35M Share Offering at $22.70/sh
-
Summit Therapeutics (SMMT) call put ratio 1.6 calls to 1 put with focus on September 15 calls after lung cancer drug shows benefits
-
BMO Capital Reiterates Outperform Rating on Merck (MRK)
-
Summit Therapeutics plc (SMMT) PT Raised to $25 at Stifel
-
Merck (MRK) Falls 5% Following Data from Summit Therapeutics (SMMT)
-
Summit Therapeutics plc (SMMT) PT Raised to $30 at H.C. Wainwright
-
Summit Therapeutics plc (SMMT) PT Raised to $19 at Citi
-
Summit (SMMT): Ivonescimab Monotherapy Reduced Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
H.C. Wainwright Starts Summit Therapeutics plc (SMMT) at Buy
-
Summit Therapeutics (SMMT) Files for 22.22M Share Offering by Selling Stockholders
-
Summit Therapeutics (SMMT) Misses Q2 EPS by 3c ; Provides Outlook
-
Citi Opens 90-Day Upside Catalyst Watch on Summit Therapeutics plc (SMMT)
-
Summit Therapeutics (SMMT) Appoints Jeff Huber to its Board
